Recursion Pharmaceuticals Inc.

RXRX | NASDAQ

$4.10

+$0.13 (+3.27%)

Sep 22, 2026, 1:48 PM ET · Market open

Fiscal Year Period Ending	FY 2025 Dec 30, 2025	FY 2024 Dec 30, 2024	FY 2023 Dec 30, 2023	FY 2022 Dec 30, 2022	FY 2021 Dec 30, 2021	FY 2020 Dec 30, 2020
Net Income	-644.76M	-463.66M	-328.07M	-239.48M	-186.48M	-87.01M
Depreciation & Amortization	83.7M	36.49M	24.4M	11.76M	8.41M	3.94M
Stock-Based Compensation	111.22M	81.69M	53.5M	27.91M	14.84M	4.29M
Other Working Capital	-16.64M	-38.37M	-35.51M	103.16M	-10M	32.14M
Other Non-Cash Items	64.34M	24.31M	6.64M	11.37M	4.1M	2.54M
Deferred Income Tax	n/a	n/a	n/a	n/a	827K	n/a
Change in Working Capital	13.69M	-38M	-44.26M	104.92M	-306K	30.83M
Operating Cash Flow	-371.81M	-359.17M	-287.78M	-83.52M	-158.61M	-45.4M
Capital Expenditures	-6.47M	-13.7M	-11.96M	-37.36M	-39.8M	-6.74M
Cash Acquisitions	n/a	277.1M	1.84M	n/a	231.95M	-2.6M
Purchase of Investments	-3.81M	n/a	n/a	n/a	-301.14M	n/a
Sales Maturities Of Investments	n/a	n/a	480K	230.61M	69.19M	n/a
Other Investing Acitivies	-6.6M	-3.35M	-597K	-300K	-231.95M	-309K
Investing Cash Flow	-16.87M	260.06M	-10.23M	193.25M	-271.74M	-8.74M
Debt Repayment	-8.43M	-4.44M	-766K	-90K	-12.8M	6.32M
Common Stock Repurchased	n/a	n/a	n/a	n/a	n/a	n/a
Dividend Paid	n/a	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	-3M	8.14M	12.81M	10.72M	8.44M	681K
Financial Cash Flow	521.53M	304.12M	140.13M	154.35M	458.54M	246.14M
Net Cash Flow	150.9M	201.6M	-157.69M	263.76M	28.18M	192M
Free Cash Flow	-378.28M	-372.87M	-300.33M	-120.88M	-198.41M	-52.13M
Adj. Free Cash Flow	-489.5M	-454.56M	-353.84M	-148.79M	-213.25M	-56.43M
Maintenance CapEx	n/a	n/a	n/a	n/a	n/a	n/a
Growth CapEx	-6.47M	-13.7M	-11.96M	-37.36M	-39.8M	-6.74M
Owner Earnings	-371.81M	-359.17M	-287.78M	-83.52M	-158.61M	-45.4M